NAMS · NASDAQ
NewAmsterdam Pharma (NAMS) Stock Price & Fundamentals
NewAmsterdam Pharma (NAMS) closed at $563.80 on Oct 9, 2026, up 1.11% from the previous close of $557.60.
Share price, past year
1Y +11.88%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $563.80 |
| Sep 30, 2026 | $558.52 |
| Aug 31, 2026 | $548.70 |
| Jul 31, 2026 | $580.86 |
| Jun 30, 2026 | $548.12 |
| May 29, 2026 | $538.60 |
| Apr 30, 2026 | $553.46 |
| Mar 31, 2026 | $541.70 |
| Feb 27, 2026 | $509.22 |
| Jan 30, 2026 | $494.41 |
| Dec 31, 2025 | $482.78 |
| Nov 28, 2025 | $507.03 |
| Oct 31, 2025 | $508.98 |
Key statistics
- Market cap
- $66.33B
- P/E (TTM)
- —
- EPS (TTM)
- −$2.15
- Revenue (TTM)
- $7.12M
- Net income (TTM)
- −$259.50M
- Shares outstanding
- 117.7M
- Dividend yield
- —
- 52-week range
- $469.47 – $583.49
NewAmsterdam Pharma's market cap is $66.33B, based on a share price of $563.80 and 117.7M shares outstanding as of Jun 30, 2026.
Financials
NewAmsterdam Pharma reported revenue of $22.50M for fiscal 2025, down 50.61% from fiscal 2024.
NewAmsterdam Pharma reported a net loss of $203.82M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $22.50M | −50.6% | −$203.82M | −905.7% | −$1.72 | — |
| FY2024ended Dec 31, 2024 | $45.56M | +223.4% | −$241.60M | −530.3% | −$2.56 | — |
| FY2023ended Dec 31, 2023 | $14.09M | −86.3% | −$176.94M | −1,255.8% | −$2.15 | — |
| FY2022ended Dec 31, 2022 | $102.69M | — | −$22.63M | −22.0% | −$1.19 | — |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $3.70M | −$64.14M | −$0.52 |
| Q1 FY2026ended Mar 31, 2026 | $3.04M | −$48.44M | −$0.40 |
| Q4 FY2025ended Dec 31, 2025 | $32.00K | −$74.92M | −$0.62 |
| Q3 FY2025ended Sep 30, 2025 | $348.00K | −$72.01M | −$0.61 |
| Q2 FY2025ended Jun 30, 2025 | $19.15M | −$17.36M | −$0.15 |
| Q1 FY2025ended Mar 31, 2025 | $2.98M | −$39.53M | −$0.34 |
| Q4 FY2024ended Dec 31, 2024 | $12.77M | −$92.18M | −$0.91 |
| Q3 FY2024ended Sep 30, 2024 | $29.11M | −$16.65M | −$0.18 |
Company profile
- Name
- NewAmsterdam Pharma Co N.V.
- Ticker
- NAMS
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- Gooimeer 2-35, Narrden, P7 1411 DC
- Incorporated in
- P7
- Fiscal year ends
- December
- SEC CIK
- 0001936258
Recent SEC filings
- Sep 29, 2026
- Sep 21, 2026
- Aug 14, 2026
- Aug 5, 2026
- Aug 5, 2026
- Jul 24, 2026
- Jul 22, 2026
- Jun 3, 2026
Frequently asked questions
What is NewAmsterdam Pharma's stock price?
NewAmsterdam Pharma (NAMS) closed at $563.80 on Oct 9, 2026, up 1.11% from the previous close of $557.60.
What is NewAmsterdam Pharma's market cap?
NewAmsterdam Pharma's market cap is $66.33B, based on a share price of $563.80 and 117.7M shares outstanding as of Jun 30, 2026.
How much revenue does NewAmsterdam Pharma make?
NewAmsterdam Pharma reported revenue of $22.50M for fiscal 2025, down 50.61% from fiscal 2024.
Does NewAmsterdam Pharma pay a dividend?
NewAmsterdam Pharma's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from NewAmsterdam Pharma Co N.V.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures